MiNK Therapeutics, Inc. Q3 FY2024 earnings call

• Added Dr. Robert Kadlec to the Board of Directors, leveraging his experience in public health and biodefense. • Clinical progress: Lead program 797 in Phase 2 trial for advanced gastric cancer with promising efficacy signals from first half of patient cohorts; data presented at SITC on 797 in combination with immune checkpoints and bispecific agents; PRAME-TCR-iNKT program discussed with pre-clinical data showing potential. • Progress in GvHD program: Phase 1 trial in development for acute GvHD, focusing on prevention and treatment of acute GvHD and other transplant outcomes; ongoing pre-clinical investigations. • Collaboration with Autonomous Therapeutics to combine encRNA tech with iNKT therapies. • Operational efficiencies: Reduced operating burn by nearly 60%, manufacturing efficiencies reducing cost of goods through scalability and single donor exploitation.

No distinct product segments with financial performance and revenue contribution % detailed in the transcript

• Look forward to strengthening cash position and identifying additional cost containment areas. • Advancing MiNK-215 program towards IND. • Updates on trial enrollments, including progress in the gastric cancer trial and GvHD program design.

• Forward-looking statements are subject to risks and uncertainties; refer to SEC filings for detailed description of risks.

Q: Comment on enrollment in the Phase 2 gastric study, data update in early 2025, and R&D expenses decline.

A: Enrollment in gastric trial is progressing, close to halfway done; data update at early 2025 conference. R&D expenses decline due to manufacturing efficiencies, scalability with single donor reducing cost of starting material for cell manufacturing, and focus on advancing MiNK-215 program and pipeline innovations.

Q: Provide color on trial design and endpoints for the graft-versus-host disease program.

A: Trial is in design phase, will have lead investigator on subsequent call; focuses on patients with hematopoietic stem cell transplantation at elevated risk for acute GvHD, eligibility includes patients with identified risk markers and minimal active infections.